Cardiac amyloidosis is subclassified based on the specific protein involved, with the major subtypes being transthyretin amyloidosis (ATTR cardiac amyloidosis), caused by misfolding of the transthyretin protein, and light chain amyloidosis (AL cardiac amyloidosis), caused by accumulation of immunoglobulin ...
Cardiac amyloidosis may manifest primarily or be discovered incidentally in patients with other signs and symptoms of systemic amyloidosis. Delay in diagnosis is common and may lead to a delay in the initiation of the treatment.[4]Cardiac involvement in systemic amyloidosis carries prognostic value and...
IgG1 antibody binding to native SAP component, a plasma protein identified in all types of amyloid deposits. In a phase 1 clinical trial conducted in patients with systemic amyloidosis, dezamizumab treatment was associated with signs of organ response such as decreases in liver stiffness, which w...
Cardiac ECV was higher in amyloid patients (definite amyloidosis, 0.43 ± 0.12; possible amyloidosis, 0.34 ± 0.11) than in control subjects (0.26 ± 0.04, p < 0.05); even in amyloid patients without late gadolinium enhancement (0.35 ± 0.10), ECV was significantly higher than in the control...
Diagnosing myocarditis is challenged by nonspecific clinical signs and symptoms and low accuracy of endomyocardial biopsy. Cardiac magnetic resonance imaging (CMR) provides both cardiac anatomy and tissue characterization in this setting, but the prognostic value of this method as a primary assessment tool...
Identifying transthyretin cardiac amyloidosis requires increased awareness of the prevalence, signs and symptoms, and diagnostic tools available for discrimination of this progressive form of cardiomyopathy associated with left ventricular hypertrophy. While there are no FDA-approved medical treatments, ...
Improvements in clinical awareness of cardiac amyloidosis have led to earlier recognition of signs and symptoms, access to diagnostics and a specialist multidisciplinary team. Yet, it remains a life-limiting disease. This editorial discusses cardiac amyloidosis and how nurses can id...
Amyloidosis is a rare systemic disease due to the extracellular tissue deposition of a fibrillar-shaped misfolded protein, called amyloid. Only two types of proteins commonly affect the heart leading to an infiltrative cardiomyopathy: immunoglobulin ligh
Echocardiography One of the first essential clues in raising suspicion for amyloidosis is echo- cardiography, as it is a mainstay in the evaluation of patients with dyspnea or heart failure symptoms. Increased LV wall thickness, particularly when combined with relative low voltage on ECG is a ...
2.5.4 Magnetic Resonance Imaging (MRI) Cardiac MRI is useful to diagnose some specific CMPs such as myocarditis, amyloidosis, sarcoidosis and infiltrative and inflammatory cardiomyopathies and arrhythmogenic right ventricular dysplasia (Maceira et al., 2005; Mahrholdt et al.,2004; Tandri et al.,...